Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma

Niccolò Bolli • 25 Sep 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

Niccolò Bolli, MD, PhD, University of Milan, Milan, Italy, comments on features that are characterized as genomically aggressive or indolent in patients with smoldering myeloma, and discusses their impact on progression to multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Niccolò Bolli

2:26
The role of the bone marrow immune microenvironment on response to treatment in multiple myeloma
Niccolò Bolli • 25 Aug 2022
2:45
Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression
Niccolò Bolli • 25 Aug 2022
2:43
Session highlights: clonal hematopoiesis in multiple myeloma
Niccolò Bolli • 25 Aug 2022
4:02
The association between CHIP and MGUS
Niccolò Bolli • 12 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals